SlideShare a Scribd company logo
1 of 1
Download to read offline
Metabolomics of Neuronal CellsMegan Gant, Marie Phelan, Jill Madine
Introduction
Neurodegenerative disease is becoming a growing problem in our ageing
society and has been described as 'the new cancer'. However, there is still
no cure. Current treatment can only begin once the condition is detected,
but in the case of Alzheimer's disease (AD) patients are often in an
advanced stage of the disease by the time a conclusive diagnosis is
possible.
Amyloid-beta (Aβ) is a misfolded protein which is considered to be one of
the major driving factors of AD. The two most studied of these proteins are
Aβ40 and Aβ42. Whilst Aβ40 is the most abundant in the AD brain, it is
estimated that Aβ42 does the real damage due to its longer length and
resulting higher aggregation potential.
The α-synuclein (α-syn) protein is a naturally occuring protein in the brain
neurons which can become overexpressed and therefore aggregate to form
insoluble plaques called Lewy bodies. The presence of Lewy bodies is a key
factor in many neurodegenerative diseases, such as Parkinson's disease.
Aβ42 and α-syn both aggregate to form insoluble plaques and both have a
similar aggregation pathway.
Methods Analysis
Principle Component Analysis
Principle component analysis (PCA) aims to accurately describe a set of data points by
reducing them down to 'principle components' based on similarity. The data points from an
NMR spectrum are collected by dividing the spectrum into statistical buckets, or sections
and each section being described as a data point.
Control α-syn Aβ
The scores plot shows the relationship between
the variables for each section of the spectrum
from two principle components and sometimes
clustering can be seen here.
The loadings plot shows all of the samples
clustered according to similarity. The data points
are then grouped into a number of principle
components.
The clustering is better observed in the 3D plot
showing the data from each sample reduced to
three principle components.
Results
Preliminary spectra showing the metabolomic profiles of
SH-SY5Y cells
Areas with the most metabolomic difference between
samples have been enlarged in the corresponding boxes.
.Below is an example of some of the metabolites that were
found with chemical groups detected by NMR highlighted in
colour:
Project
●This project aims to use NMR metabolomics techniques to assess the influence
of Aβ and α-syn on SH-SY5Y neuroblastoma cells
●Identification of metabolite alteration will be used to identify changes in cellular
pathways which might impact the functionality of the cell
●The will give insight into the toxicity of Aβ and α-syn
●Future work will include testing Aβ and α-syn at different stages of aggregation
and testing different conformations of oligomer.
Institute of Integrative Biology, Biosciences Building, University of Liverpool, Crown Street, Liverpool L69 7ZB
Alanine Lactate
Glutamine
Metabolites and Pathways
Acetate Creatine Glutamate
Citrate Cycle (TCA Cycle)
Alanine, Aspartate and
Glutamate Metabolism
L- AlaninePyruvate
Acetyl-CoA Acetate
L-Lactate
Urea Cycle Creatine Urea
L-GlutamateSuccinate
L-Glutamine
Pathways simplified from KEGG database
Between
Pathways
Within
Pathways
Pathway
Unidirectional
Reversible
SH-SY5Y with Aβ
SH-SY5Y with α-syn
SH-SY5Y
2-oxa glutarate
Succinate
2 Oxa
Glutarate Glucose
Glycolysis Glucose
PurineAminosugars
The box plot shows the variation of an unknown
metabolite between the three sample groups
Control
α-syn
Aβ
●The variation of metabolites mean that
the cellular pathways associated with
the metabolite have been affected by
the protein.
●This can tell us how cell function
changes in the presence of the proteins.
● Below is an example of pathways
affected by changing metabolites found
in the preliminary spectra (Results, left).

More Related Content

Viewers also liked (13)

Physiology nobel laureates
Physiology nobel laureatesPhysiology nobel laureates
Physiology nobel laureates
 
Lincl katz
Lincl katzLincl katz
Lincl katz
 
CURC FINAL
CURC FINALCURC FINAL
CURC FINAL
 
BDSRA 2015 CLN1 Wishart
BDSRA 2015 CLN1 Wishart BDSRA 2015 CLN1 Wishart
BDSRA 2015 CLN1 Wishart
 
PROTEIN TARGETING
PROTEIN TARGETINGPROTEIN TARGETING
PROTEIN TARGETING
 
!Mechanism of protein sorting & targeting.
!Mechanism of protein sorting & targeting.!Mechanism of protein sorting & targeting.
!Mechanism of protein sorting & targeting.
 
Protein targeting ajay
Protein targeting ajayProtein targeting ajay
Protein targeting ajay
 
Protein folding and aggregation
Protein folding and aggregationProtein folding and aggregation
Protein folding and aggregation
 
Protein structure, targeting and sorting
Protein structure, targeting and sortingProtein structure, targeting and sorting
Protein structure, targeting and sorting
 
Protein transport, targeting and sorting
Protein transport, targeting and sortingProtein transport, targeting and sorting
Protein transport, targeting and sorting
 
Neurodegenerative diseases
Neurodegenerative diseases Neurodegenerative diseases
Neurodegenerative diseases
 
Protein targeting
Protein targetingProtein targeting
Protein targeting
 
Protein sorting and targeting
Protein sorting and targetingProtein sorting and targeting
Protein sorting and targeting
 

Similar to finalposter_ARUKpdf

Development and implementation of a novel interactome platform in studies on ...
Development and implementation of a novel interactome platform in studies on ...Development and implementation of a novel interactome platform in studies on ...
Development and implementation of a novel interactome platform in studies on ...Ewelina Maliszewska-Cyna, PhD
 
Dementia and its treatmentThis chapter will provide a brie.docx
Dementia and its treatmentThis chapter will provide a brie.docxDementia and its treatmentThis chapter will provide a brie.docx
Dementia and its treatmentThis chapter will provide a brie.docxcuddietheresa
 
Dementia and its treatmentThis chapter will provide a brie.docx
Dementia and its treatmentThis chapter will provide a brie.docxDementia and its treatmentThis chapter will provide a brie.docx
Dementia and its treatmentThis chapter will provide a brie.docxcargillfilberto
 
Amyloid and alzheimer’s disease
Amyloid and alzheimer’s diseaseAmyloid and alzheimer’s disease
Amyloid and alzheimer’s diseaseNikhil Agrawal
 
Emerging Trends in Alzheimer’s Disease by Dr. Seema.ppt
Emerging Trends in Alzheimer’s Disease by Dr. Seema.pptEmerging Trends in Alzheimer’s Disease by Dr. Seema.ppt
Emerging Trends in Alzheimer’s Disease by Dr. Seema.pptDrSeemaBansal
 
Amyloid diseases- Is there light at the end of the tunnel_
Amyloid diseases- Is there light at the end of the tunnel_Amyloid diseases- Is there light at the end of the tunnel_
Amyloid diseases- Is there light at the end of the tunnel_Jonathon Burke
 
Alzheimer’s/Mild Cognitive Impairment Program
Alzheimer’s/Mild Cognitive Impairment ProgramAlzheimer’s/Mild Cognitive Impairment Program
Alzheimer’s/Mild Cognitive Impairment ProgramEgor Sulkin
 
Spilman tropisetron brain research
Spilman tropisetron brain researchSpilman tropisetron brain research
Spilman tropisetron brain researchpatricia spilman
 
Group 3 - Protein folding - Recent Development - Cause of Alzheimer's Disea...
Group 3 - Protein folding  - Recent Development  - Cause of Alzheimer's Disea...Group 3 - Protein folding  - Recent Development  - Cause of Alzheimer's Disea...
Group 3 - Protein folding - Recent Development - Cause of Alzheimer's Disea...NafeesaHanif1
 
Apolipoprotein E in Alzheimer diesease.pdf
Apolipoprotein E in Alzheimer diesease.pdfApolipoprotein E in Alzheimer diesease.pdf
Apolipoprotein E in Alzheimer diesease.pdfAnaPaulinaCardonaOla
 

Similar to finalposter_ARUKpdf (20)

Lit Review
Lit ReviewLit Review
Lit Review
 
APOE Poster
APOE PosterAPOE Poster
APOE Poster
 
AN_A&D2016
AN_A&D2016AN_A&D2016
AN_A&D2016
 
Neuroimmunology update
Neuroimmunology updateNeuroimmunology update
Neuroimmunology update
 
Development and implementation of a novel interactome platform in studies on ...
Development and implementation of a novel interactome platform in studies on ...Development and implementation of a novel interactome platform in studies on ...
Development and implementation of a novel interactome platform in studies on ...
 
Dementia and its treatmentThis chapter will provide a brie.docx
Dementia and its treatmentThis chapter will provide a brie.docxDementia and its treatmentThis chapter will provide a brie.docx
Dementia and its treatmentThis chapter will provide a brie.docx
 
Dementia and its treatmentThis chapter will provide a brie.docx
Dementia and its treatmentThis chapter will provide a brie.docxDementia and its treatmentThis chapter will provide a brie.docx
Dementia and its treatmentThis chapter will provide a brie.docx
 
Thesis_Ravvin
Thesis_RavvinThesis_Ravvin
Thesis_Ravvin
 
Amyloid and alzheimer’s disease
Amyloid and alzheimer’s diseaseAmyloid and alzheimer’s disease
Amyloid and alzheimer’s disease
 
Emerging Trends in Alzheimer’s Disease by Dr. Seema.ppt
Emerging Trends in Alzheimer’s Disease by Dr. Seema.pptEmerging Trends in Alzheimer’s Disease by Dr. Seema.ppt
Emerging Trends in Alzheimer’s Disease by Dr. Seema.ppt
 
Alzheimer disease
Alzheimer diseaseAlzheimer disease
Alzheimer disease
 
aguzzi2010.pdf
aguzzi2010.pdfaguzzi2010.pdf
aguzzi2010.pdf
 
Myelination
MyelinationMyelination
Myelination
 
Amyloid diseases- Is there light at the end of the tunnel_
Amyloid diseases- Is there light at the end of the tunnel_Amyloid diseases- Is there light at the end of the tunnel_
Amyloid diseases- Is there light at the end of the tunnel_
 
Alzheimer’s/Mild Cognitive Impairment Program
Alzheimer’s/Mild Cognitive Impairment ProgramAlzheimer’s/Mild Cognitive Impairment Program
Alzheimer’s/Mild Cognitive Impairment Program
 
Spilman tropisetron brain research
Spilman tropisetron brain researchSpilman tropisetron brain research
Spilman tropisetron brain research
 
Ming Resume
Ming ResumeMing Resume
Ming Resume
 
Group 3 - Protein folding - Recent Development - Cause of Alzheimer's Disea...
Group 3 - Protein folding  - Recent Development  - Cause of Alzheimer's Disea...Group 3 - Protein folding  - Recent Development  - Cause of Alzheimer's Disea...
Group 3 - Protein folding - Recent Development - Cause of Alzheimer's Disea...
 
Alzheimer disease (ad)
Alzheimer disease (ad)Alzheimer disease (ad)
Alzheimer disease (ad)
 
Apolipoprotein E in Alzheimer diesease.pdf
Apolipoprotein E in Alzheimer diesease.pdfApolipoprotein E in Alzheimer diesease.pdf
Apolipoprotein E in Alzheimer diesease.pdf
 

finalposter_ARUKpdf

  • 1. Metabolomics of Neuronal CellsMegan Gant, Marie Phelan, Jill Madine Introduction Neurodegenerative disease is becoming a growing problem in our ageing society and has been described as 'the new cancer'. However, there is still no cure. Current treatment can only begin once the condition is detected, but in the case of Alzheimer's disease (AD) patients are often in an advanced stage of the disease by the time a conclusive diagnosis is possible. Amyloid-beta (Aβ) is a misfolded protein which is considered to be one of the major driving factors of AD. The two most studied of these proteins are Aβ40 and Aβ42. Whilst Aβ40 is the most abundant in the AD brain, it is estimated that Aβ42 does the real damage due to its longer length and resulting higher aggregation potential. The α-synuclein (α-syn) protein is a naturally occuring protein in the brain neurons which can become overexpressed and therefore aggregate to form insoluble plaques called Lewy bodies. The presence of Lewy bodies is a key factor in many neurodegenerative diseases, such as Parkinson's disease. Aβ42 and α-syn both aggregate to form insoluble plaques and both have a similar aggregation pathway. Methods Analysis Principle Component Analysis Principle component analysis (PCA) aims to accurately describe a set of data points by reducing them down to 'principle components' based on similarity. The data points from an NMR spectrum are collected by dividing the spectrum into statistical buckets, or sections and each section being described as a data point. Control α-syn Aβ The scores plot shows the relationship between the variables for each section of the spectrum from two principle components and sometimes clustering can be seen here. The loadings plot shows all of the samples clustered according to similarity. The data points are then grouped into a number of principle components. The clustering is better observed in the 3D plot showing the data from each sample reduced to three principle components. Results Preliminary spectra showing the metabolomic profiles of SH-SY5Y cells Areas with the most metabolomic difference between samples have been enlarged in the corresponding boxes. .Below is an example of some of the metabolites that were found with chemical groups detected by NMR highlighted in colour: Project ●This project aims to use NMR metabolomics techniques to assess the influence of Aβ and α-syn on SH-SY5Y neuroblastoma cells ●Identification of metabolite alteration will be used to identify changes in cellular pathways which might impact the functionality of the cell ●The will give insight into the toxicity of Aβ and α-syn ●Future work will include testing Aβ and α-syn at different stages of aggregation and testing different conformations of oligomer. Institute of Integrative Biology, Biosciences Building, University of Liverpool, Crown Street, Liverpool L69 7ZB Alanine Lactate Glutamine Metabolites and Pathways Acetate Creatine Glutamate Citrate Cycle (TCA Cycle) Alanine, Aspartate and Glutamate Metabolism L- AlaninePyruvate Acetyl-CoA Acetate L-Lactate Urea Cycle Creatine Urea L-GlutamateSuccinate L-Glutamine Pathways simplified from KEGG database Between Pathways Within Pathways Pathway Unidirectional Reversible SH-SY5Y with Aβ SH-SY5Y with α-syn SH-SY5Y 2-oxa glutarate Succinate 2 Oxa Glutarate Glucose Glycolysis Glucose PurineAminosugars The box plot shows the variation of an unknown metabolite between the three sample groups Control α-syn Aβ ●The variation of metabolites mean that the cellular pathways associated with the metabolite have been affected by the protein. ●This can tell us how cell function changes in the presence of the proteins. ● Below is an example of pathways affected by changing metabolites found in the preliminary spectra (Results, left).